US20260108572A1 - Alzheimer's Dementia Suppressant Using Sesamum Indicum Extract
Summary
USPTO published patent application US20260108572A1, filed September 1, 2023 and made publicly available on April 23, 2026, disclosing an Alzheimer-type dementia suppressant composition and method of manufacture using an aboveground part of Sesamum indicum (sesame plant) or an extract thereof as the active ingredient. The application names Sakamoto Yakusouen, LLC as assignee and Johji YAMAHARA as inventor. CPC classifications include A61K 36/185, A61K 31/7048, A61P 25/28, and related formulation codes A61K 2236/17, A61K 2236/333, A61K 2236/51, and A61K 2236/53. The application does not yet represent an issued patent and carries no compliance obligation.
“The Alzheimer-type dementia suppressant according to the present invention is characterized in comprising an aboveground part of Sesamum indicum or an extract thereof as an active ingredient.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
USPTO published patent application US20260108572A1 for an Alzheimer-type dementia suppressant and associated production method, with Sesamum indicum aboveground plant parts or extracts as the active ingredient. The application was originally filed on September 1, 2023 under application number 19115969 and became publicly available on April 23, 2026. No patent has yet been granted; this publication does not create any enforceable IP rights or compliance obligations. Competitors in the dementia-treatment or nutritional-supplement space should monitor this application's prosecution to assess potential freedom-to-operate implications if the patent issues.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ALZHEIMER-TYPE DEMENTIA SUPPRESSANT, AND METHOD FOR PRODUCING SAME
Application US20260108572A1 Kind: A1 Apr 23, 2026
Assignee
Sakamoto Yakusouen, LLC
Inventors
Johji YAMAHARA
Abstract
The objective of the present invention is to provide an Alzheimer-type dementia suppressant that is safe and thus can be administered daily and utilized as a health food and by which Alzheimer-type dementia can be suppressed, and a method for producing the Alzheimer-type dementia suppressant. In addition, the objective of the present invention is also to provide a use of an aboveground part of Sesamum indicum or an extract thereof for suppressing Alzheimer-type dementia, and a method for suppressing Alzheimer-type dementia. The Alzheimer-type dementia suppressant according to the present invention is characterized in comprising an aboveground part of Sesamum indicum or an extract thereof as an active ingredient.
CPC Classifications
A61K 36/185 A61K 31/7048 A61P 25/28 A61K 2236/17 A61K 2236/333 A61K 2236/51 A61K 2236/53
Filing Date
2023-09-01
Application No.
19115969
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.